摘要
目的:系统评价丹参多酚酸盐治疗慢性肾功能衰竭临床使用的疗效和安全性。方法:通过全面检索与丹参多酚酸盐相关的随机对照研究文献,进行质量评价,纳入合格文献进行Meta分析。结果:8个随机对照实验纳入系统评价,Meta分析结果显示丹参多酚酸盐联合常规治疗在整体临床症状、肾小球透过率、肾功能的改善和其他相关指标改善方面均优于单纯使用常规治疗。整体临床疗效比较OR值为3.22,95%可信区间为(1.61,6.38);肾小球透过率改善情况比较[WMD=11.36,95%CI(6.64,16.08)];肾功能血肌酐和尿素氮改善水平分别为[WMD=38.35,95%CI(1.47,75.24)]和[WMD=1.84,95%CI(0.97,2.70)];尿微量蛋白改善水平比较[WMD=6.52,95%CI(-1.86,14.90)];β2微球蛋白改善水平比较[WMD=1.41,95%CI(1.04,1.79)];胱抑素C改善水平比较[WMD=0.56,95%CI(0.11,1.01)];尿肌酐改善水平比较[WMD=6.77,95%CI(2.18,11.36)];血红蛋白改善水平比较[WMD=12.60,95%CI(7.44,17.77)]。结论:丹参多酚酸盐联合常规治疗用于慢性肾功能衰竭可能取得较单一常规治疗更好的效果,且无明显不良反应发生,但还需要设计良好的随机对照及多中心临床试验做进一步证实。
Objective： The aim of this study was to systematically assess the effect and safety of salvianolate on chronic renal failure （CRF）. Method： The reports about randomized controlled trials of Salvianolate were comprehensively search, and the quality was evaluated. Then the Meta analysis of those reports meeting the criteria was carried out. Result： In this study, 8 randomized controlled trials were included for the systematic review. A Meta-analysis showed that the combination of salvianolate and conventional treatment had better efficacy on both overall clinical manifestations and GRF than the conventional monotherapy. The odds ratio （OR） and 95% confidence interval （95% CI） from the comparison of the improvement on overall clinical manifestations were 3.22 and （ 1.61, 6.38） respectively. The level of GRF was [ WMD = 11.36, 95% CI （6.64, 16.08）], the level of SCR and BUN were as following： [WMD =38.35, 95%CI （1.47, 75.24）] and [ WMD = 1.84, 95% CI （0.97, 2.70） ] respectively, and the microalbuminuria level was [ WMD = 6.52, 95%CI （ -1.86, 14.90）], theβ2-microglobulin Ievel was [WMD =1.41, 95%CI （1.04, 1.79）], and the levels of cystatin C, UCR and HGB were as the following： [WMD =0.56, 95%CI （0.11, 1.01） ], [WMD = 0.56, 95%CI （0. 11, 1.01）] and [WMD = 12.60, 95% CI （7.44, 17.77）], respectively. Conclusion： The combination of salvianolate and conventional treatment may have better effectiveness and safety for CRF than the regular conventional treatment, however, well designed randomized controlled multicenter clinical trial are needed for further confirmation.
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2015年第14期203-208,共6页
Chinese Journal of Experimental Traditional Medical Formulae
基金
浙江省中西医结合学会临床药学科研专项基金项目(2013LYSX015)
浙江省药学会医院药学科研专项基金项目(2013ZYY17)
